A phase IIIB multicenter, randomized, double-blind, placebo-controlled study to assess short-term changes in synovitis and structural damage outcomes in subjects with active rheumatoid arthritis and inadequate response to methotrexate, treated with abatacept [BMS-188667] versus placebo on a background therapy with methotrexate.

Trial Profile

A phase IIIB multicenter, randomized, double-blind, placebo-controlled study to assess short-term changes in synovitis and structural damage outcomes in subjects with active rheumatoid arthritis and inadequate response to methotrexate, treated with abatacept [BMS-188667] versus placebo on a background therapy with methotrexate.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Abatacept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Acronyms ASSET
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 12 Aug 2012 Results published Annals of the Rheumatic Diseases.
    • 15 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top